ScholarIQanswers from OpenAlex
Inflammasome and immune disorders
TopicLeading institutions, researchers & key papers
Inflammasome and immune disorders is a topic indexed in ScholarIQ from OpenAlex.
What is known about Inflammasome and immune disorders?
ScholarIQrecord summary
This cluster of papers focuses on the molecular mechanisms of inflammasome activation, regulation, and its role in inflammatory responses, cell death (pyroptosis), and immune-related diseases. It covers topics such as NLRP3 inflammasome, interleukin-1, caspase-1, and the involvement of mitochondria in inflammasome activation.
How many works does Inflammasome and immune disorders have?
ScholarIQindexed works
Inflammasome and immune disorders has 398 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Inflammasome and immune disorders?
ScholarIQopenalex
The OpenAlex for Inflammasome and immune disorders is on the source record.
What are the most-cited papers on Inflammasome and immune disorders?
ScholarIQmost cited works
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Brendan M. Everett, Tom Thurén, Jean MacFadyen, William H. Chang, Christie M. Ballantyne, Francisco Antônio Helfenstein Fonseca, José Carlos Nicolau, Wolfgang Köenig, Stefan D. Anker, John J.P. Kastelein, Jan H. Cornel, Prem Pais, Daniel Pella, Jacques Genest, Renata Cífková, Alberto Lorenzatti, Tamás Forster, Zhanna Kobalava, L Vida-Simiti, Marcus Flather, Hiroaki Shimokawa, Hisao Ogawa, Mikael Dellborg, Paulo R.F. Rossi, Roland P.T. Troquay, Peter Libby, Robert J. Glynn
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean‐Claude Tardif, Simon Kouz, David D. Waters, Olivier F. Bertrand, Rafael Díaz, Aldo P. Maggioni, Fausto J. Pinto, Réda Ibrahim, Habib Gamra, Ghassan S. Kiwan, Colin Berry, José López‐Sendón, Petr Ošťádal, Wolfgang Köenig, Denis Angoulvant, Jean C. Grégoire, Marc-André Lavoie, Marie‐Pierre Dubé, David Rhainds, Mylène Provencher, Lucie Blondeau, Andreas Orfanos, Philippe L. L’Allier, Marie‐Claude Guertin, François Roubille
Colchicine in Patients with Chronic Coronary Disease
Stefan M. Nidorf, Aernoud T.L. Fiolet, Arend Mosterd, John W. Eikelboom, Astrid Schut, Tjerk S.J. Opstal, Salem H.K. The, Xiao-Fang Xu, Mark A. Ireland, Timo Lenderink, Donald Latchem, Pieter Hoogslag, Anastazia Jerzewski, Peter R Nierop, Alan Whelan, Randall Hendriks, Henk P. Swart, Jeroen Schaap, Aaf F.M. Kuijper, M. W. J. van Hessen, Pradyot Saklani, Isabel Tan, Angus Thompson, Allison Morton, Chris Judkins, Willem A. Bax, Maurits T. Dirksen, Marco Alings, Graeme J. Hankey, Charley Budgeon, Jan G.P. Tijssen, Jan H. Cornel, Peter L. Thompson
Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes
Michael McDermott, Ivona Aksentijevich, Jérôme Galon, Elizabeth McDermott, B Ogunkolade, Michael Centola, Elizabeth Mansfield, Massimo Gadina, Leena Karenko, Tom Pettersson, John McCarthy, David M. Frucht, Martin Aringer, Yelizaveta Torosyan, Anna‐Maija Teppo, Meredith Wilson, H.Mehmet Karaarslan, Ying Wan, Ian Todd, Geryl Wood, Ryan Schlimgen, Thisum R. Kumarajeewa, Sheldon M. Cooper, John P. Vella, Christopher I. Amos, John C. Mulley, Kathleen A. Quane, Michael G. Molloy, Annamari Ranki, Richard J. Powell, G. A. Hitman, John J. O’Shea, Daniel L. Kastner
Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria
Edward A. Miao, Irina A. Leaf, Piper M. Treuting, Dat P. Mao, Monica Dors, Anasuya Sarkar, Sarah Warren, Mark D. Wewers, Alan Aderem
Where is Inflammasome and immune disorders research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Inflammasome and immune disorders is open access?
ScholarIQopen access share
73%OPEN ACCESS